Announcement

Collapse
No announcement yet.

Drug Discov Ther. Treat 2019 novel coronavirus (COVID-19) with IL-6 inhibitor: Are we already that far?

Collapse
X
Collapse
 
  • Page of 1
  • Filter
  • Time
  • Show
Clear All
new posts
Previous template Next
  • #1

    Drug Discov Ther. Treat 2019 novel coronavirus (COVID-19) with IL-6 inhibitor: Are we already that far?


    Drug Discov Ther. 2020;14(2):100-102. doi: 10.5582/ddt.2020.03006.
    Treat 2019 novel coronavirus (COVID-19) with IL-6 inhibitor: Are we already that far?


    Zhang Y1, Zhong Y1, Pan L1, Dong J1.

    Author information




    Abstract

    The world is in the midst of the coronavirus disease 2019 (COVID-19) pandemic. Interleukin 6 (IL-6) inhibitor (tocilizumab) had been suggested for the treatment of acute respiratory distress syndrome (ARDS) patients based on the concept of "cytokine storm" in COVID-19. However, we still lack reliable studies to verify "cytokine storm" in COVID-19 pneumonia. Furthermore, IL-6 inhibitor has potential hazards of inducing infectious diseases. The efficacy of IL-6 monoclonal antibody-directed therapy remains to be fully evaluated.



    KEYWORDS:

    coronavirus; cytokine storm; pneumonia; tocilizumab


    PMID:32378647DOI:10.5582/ddt.2020.03006


    Tags: None
Previous template Next
Working...
X